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ABSTRACT  
Study Design 
This was a randomised controlled trial in patients with degenerative disc disease 
(DDD) who underwent instrumented posterolateral lumbar fusion (PLF) surgery.  
Objective  
The aim of this study was to assess the efficacy of the bone grafting substitute, 
silicate-substituted calcium phosphate (SiCaP) compared with bone morphogenetic 
protein (rhBMP-2) and to evaluate clinical outcomes over a period of two years.  
Methods  
Patients undergoing PLF surgery for DDD at a single centre were recruited and 
randomised to one of two groups; SiCaP (n=9) or rhBMP-2 (n=10). One patient 
withdrew prior to randomisation and another from the rhBMP-2 group after 
randomisation. The radiological and clinical outcomes were examined and compared. 
Fusion was assessed at 12 months with computed tomography (CT) and plain 
radiographs. Clinical outcomes were evaluated by recording measures of pain, quality 
of life, disability and neurological status from six weeks to two years postoperatively. 
Results 
In the SiCaP and rhBMP-2 groups, fusion was observed in 9/9 and 8/9 patients 
respectively. Pain and disability scores were reduced and quality of life increased in 
both groups.  Leg pain, disability and satisfaction scores were similar between the 
groups at each postoperative time point, however, back pain was less at six weeks and 
quality of life was higher at six months in the SiCaP group than the rhBMP-2 group.  
Abstract
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Conclusions 
SiCaP and rhBMP-2 were comparable in terms of achieving successful bone growth 
and fusion.  Both groups similarly alleviated pain and improved quality of life, 
neurological, satisfaction and return to work outcomes following PLF surgery.   
 
1 
STUDY RATIONALE AND CONTEXT  1 
rhBMP-2 is used as an alternative to iliac crest bone in PLF surgery but there are potential 2 
concerns about the cost and associated complications including radiculitis, ectopic bone 3 
formation and osteolysis. 1-4  SiCaP has been proposed as a viable option in spinal fusion 4 
procedures, in conjunction with appropriate stabilizing hardware.5 However, it is unclear 5 
whether it is as effective in achieving a solid arthrodesis, particularly in the setting on PLF.  6 
OBJECTIVE 7 
To compare fusion success at 12 months and clinical outcomes over a period of two years in 8 
patients with DDD who underwent instrumented PLF surgery with either SiCaP or rhBMP-2 9 
as bone grafting materials.   10 
METHODS  11 
Study Design: This was a Phase IV randomised controlled trial of patients undergoing 12 
instrumented PLF. Randomisation was performed centrally on a 1:1 basis and conveyed by 13 
sealed envelope. Patients and radiologists were blinded to surgical treatment. 14 
Inclusion Criteria: Patients presenting to a single centre between July 2009 and July 2010 15 
were screened for eligibility. Patients aged 18–80 years with DDD of the lumbar spine that 16 
had failed to respond to non-operative treatment for at least six months and that were 17 
considered suitable for PLF surgery were included.  18 
Exclusion criteria: Patients were excluded if they had undergone previous fusion attempts, 19 
required surgery at more than two levels, had recent or ongoing infection, osteoporosis 20 
(excluding osteopenia) or other significant medical condition or were taking medication 21 
which may have interfered with bone metabolism.  22 
Patient Population: Thirty-three patients were assessed for eligibility. Fourteen were 23 
excluded and 19 patients underwent randomisation. Nine patients were in the SiCaP group 24 
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2 
and ten in the rhBMP-2 comparator group, from which one patient withdrew. In total 9 25 
patients were analysed for each group. (Fig.1). 26 
Intervention: Through a midline approach, pedicle screws were inserted. Transverse 27 
processes and facet joints were exposed and decorticated. SiCaP in the form of Actifuse 28 
(Baxter) or rhBMP-2 in the form of Infuse (Medtronic) and Mastergraft (Medtronic) was 29 
packed in the facet joints and posterolateral gutters. 10 to 15ml of Actifuse was used per level 30 
per side.  One large Infuse sponge (12mg rhBMP-2, 1.5mg/ml) wrapped around 15cc 31 
Mastergraft calcium phosphate ceramic granules was used per level, with half in each 32 
posterolateral gutter.  33 
Outcomes:  34 
 Fusion success was assessed with CT scans 12 months after surgery and with plain 35 
radiographs taken at 3-, 6-, 12-, and 24-months after surgery. Images were assessed 36 
by two radiographic reviewers blinded to the intervention. Solid fusion on CT was 37 
based on bridging trabecular bone between transverse processes in the posterolateral 38 
gutters and graded according to previous methodology.2  Grade 4 (solid unilateral 39 
fusion) or grade 5 (solid bilateral fusion) was deemed solid fusion.  Solid fusion on 40 
plain x-ray was based on the absence of motion, which was defined as no more than 41 
3mm translation or 5 degrees of angulation on flexion extension views. To be 42 
considered fused, both imaging modalities needed to demonstrate fusion.  43 
 Data were recorded before and 6 weeks, 3-, 6-, 12- and 24-months after surgery for: 44 
visual analogue scale (VAS) of back and leg (left and right) pain status 6; the 45 
Oswestry Disability Index (ODI) 7,8 ; quality of life outcomes using the 36-Item Short 46 
Form Health Survey (SF-36) 9, neurological status; patients’ general satisfaction and 47 
changes in work status.   48 
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 Neurological status was based on physical examination of four measurements; motor 49 
function, sensory function, reflexes and straight leg raise. Satisfaction and change in 50 
work status was assessed based on patient’s response to specific questions. 51 
 Safety was assessed in terms of adverse events (AEs).  52 
 53 
Analysis: T-tests and Fisher’s exact tests (using SAS® software version 9.1.3.) were used to 54 
obtain p-values for continuous and categorical data respectively. Improvement in back and 55 
leg VAS, ODI and quality of life outcomes using SF-36 were analysed based on achievement 56 
of minimum clinically important difference (MCID) at all post-operative time points.10  57 
58 
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4 
RESULTS  59 
Patient Characteristics: 19 patients were enrolled, one patient withdrew from the rhMBP-2 60 
group, leaving nine patients in each group (Fig.1). A summary of demographic information is 61 
provided in Table 1. All patients had degenerative disc disease. In all cases, the primary 62 
diagnosis was spinal stenosis with or without degenerative spondylolisthesis. 63 
Primary Outcome Results: 64 
 Fusion occurred in 9/9 patients in the SiCaP group (Fig.2) and 8/9 patients in the 65 
rhBMP-2 group, p= ns (Fig.3).  66 
Secondary Outcome Results: 67 
 Minimum clinically important difference (MCID) for ODI was achieved by a greater 68 
proportion of patients in the SiCaP group at all post-operative time points. However, 69 
this difference was not significant (Table 2). 70 
 There was no significant difference between the SiCaP and rhBMP-2 groups in the 71 
percentage of patients achieving MCID for Physical Component Summary scores at 72 
any of the post-operative time points (Table 2). 73 
 When compared to their pre-operative scores, majority of patients in both the SiCaP 74 
and rhBMP-2 groups reported a reduction in back and leg VAS at the 6 month 75 
postoperative review. However, not all of these patients achieved a minimal clinically 76 
significant difference. There does not appear to be a difference between groups but 77 
there does appear to be a trend towards a higher pre-operative VAS relating to a 78 
greater reduction in VAS at the 6 months postoperative review (Fig.4-6). 79 
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5 
 Patients reported improved neurological status, general satisfaction and no change in 80 
employment after surgery. There were no significant differences between SiCaP and  81 
rhBMP-2 groups at any of the postoperative time points.   82 
 There were no adverse events attributable to the bone graft material in either group. 83 
 84 
DISCUSSION  85 
 rhBMP-2 is widely used in bone graft applications in the lumbar spine and 86 
demonstrates higher-grade fusions than iliac crest bone graft. 2, 3 However, questions 87 
regarding the safety profile of rhBMP-2 in spinal surgery have been raised4.  The 88 
osteoconductive bone graft material, SiCaP has recently gained considerable attention 89 
and has been used in a case series of 42 patients undergoing PLF surgery with 90 
reported fusion rates of 76%. 11  91 
 This is the first randomised trial to evaluate the effects of using SiCaP relative to 92 
rhBMP-2 in this particular PLF surgical setting. 93 
 We observed postoperative fusion rates of 100% at 12 months with SiCaP, confirming 94 
the usefulness of SiCaP in the context of PLF for patients with DDD.   95 
 These results suggest similar rates of fusion and clinical outcomes in patients 96 
receiving PLF procedures with SiCaP or rhBMP-2.  97 
 The low patient numbers in this study were largely due to most patients being 98 
excluded after being screened and deemed suitable for interbody fusion rather than 99 
posterolateral fusion. Posterolateral fusion was chosen as the surgical technique in this 100 
study as it provides a more demanding environment for fusion. 101 
 Further investigations using large numbers of subjects will be beneficial in providing 102 
information about the efficacy and safety of SiCaP as a bone grafting substitute.    103 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6 
SUMMARY AND CONCLUSION  104 
 SiCaP and rhBMP-2 substitute bone graft biomaterials were comparable in terms of 105 
achieving successful bone growth and bone fusion, and similarly alleviated pain and 106 
improved quality of life, neurological outcomes, general satisfaction and work status 107 
change following PLF surgery.  108 
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FIGURES 156 
Fig. 1.  CONSORT diagram of patient selection.  157 
 158 
Fig. 2. Illustrative CT images acquired 12 months after posterolateral fusion surgery with 159 
SiCaP of four patients who achieved a solid fusion (A-D).   160 
 161 
Fig. 3. Illustrative CT images acquired 12 months after posterolateral fusion surgery with 162 
rhBMP-2 of four patients who achieved a solid fusion (A-D).  163 
  164 
Fig. 4. Visual analogue scale (VAS) for back pain.  The VAS score was assessed from zero 165 
(no pain) to 10 (greatest pain). MCID represents the minimal clinically important difference, 166 
demonstrated at -1.2 10. 167 
 168 
Fig. 5. Visual analogue scale (VAS) for left leg pain. The VAS score was assessed from zero 169 
(no pain) to 10 (greatest pain). MCID represents the minimal clinically important difference, 170 
demonstrated at -1.6 10. 171 
 172 
Fig.6. Visual analogue scale (VAS) for right leg pain. The VAS score was assessed from zero 173 
(no pain) to 10 (greatest pain).  MCID represents the minimal clinically important difference, 174 
demonstrated at -1.6 10. 175 
 176 
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Table 1. Patient Characteristics 
Sample Characteristic SiCaP BMP-2 Total 
Age, years ± SD 65.8 ± 7.17 66.9 ± 6.54 66.4 ± 6.68 
n 9 10 19 
Height, cm ± SD 173.8 ±11.68 167.0 ±11.31 170.4 ±11.64 
n 9 10 19 
Weight, kg ± SD 88.1 ±23.36 81.5 ±15.08 84.8 ±19.30 
n 9 10 19 
Body mass index, kg/m2 ± SD 28.9 ±5.82 30.1 ±2.93 29.4 ±4.49 
n 9 10 19 
Obese, n 4 3 7 
Sex   
Male 6 (67%) 3 (30%) 9 (47%) 
Female 3 (33%) 7 (70%) 10 (53%) 
Smoker  (n [%])    
No 8 (89%) 10 (100%) 18 (95%) 
Yes 1 (11%) 0 (0%) 1 (5%) 
 
Values are expressed as mean (± SD); n: number of patients; obesity was defined as having a body mass index 
>30 kg/m2.  
Table 1
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Table 2. Comparision of Oswestry Disability Index (ODI) and Quality of Life 36-Item Short 
Form Health Survey (SF-36) Physical Component Summary scores 
Oswestry Disability Index (ODI) scores – Percentage achieveing MCID, 
compared to pre-operative score 
Time-point SiCaP rhBMP-2 p-value 
6 Weeks 75.0% (6/8) 25.0% (2/8) 0.13 
3 Months 85.7% (6/7) 50.0% (4/8) 0.28 
6 Months 87.5% (7/8) 44.4% (4/9) 0.13 
12 Months 100% (8/8) 55.6% (5/9) 0.08 
24 Months 87.5% (7/8) 66.7% (6/9) 0.58 
Quality of Life 36-Item Short Form Health Survey (SF-36) Physical Component 
Summary scores – Percentage achieving MCID, compared to pre-operative score 
Time-point SiCaP rhBMP-2 p-value 
6 Weeks 87.5% (7/8) 75% (6/8) 1.00 
3 Months 100% (7/7) 87.5% (7/8) 1.00 
6 Months 100% (8/8) 100% (9/9) 1.00 
12 Months 100% (8/8) 100%  (8/8) 1.00 
24 Months 100% (8/8) 100% (9/9) 1.00 
 
SiCaP: silicated calcium phosphate bone graft; rhBMP-2: bone morphogenetic protein-2. n: number of 
patients p-values for between group comparisons. Significant difference if p-values <0.05. 
MCID (Minimum Clinically Important Difference) calculation was based on 12.8 points for ODI and 4.9 
points for SF-36 PCS (Physical Component Summary)10. 
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